“…The importance of giving RAI to those patients is also reinforced by the fact that, in our cohort, patients with I131 treatment were similar at baseline to those who didn't receive it (similar data for TNM stage, metastases in other locations and pulmonary metastases, which were the factors associated with mortality in our study). The uptake of I131 by BMs was also significant as a protective factor in the univariate analysis, a result consistent with those of other authors ( 6 , 14 , 17 , 28 , 29 ). Regarding the combination of I131 with other treatments, this was not shown to improve survival in our cohort, contrary to the results of other studies ( 2 , 4 , 30 , 31 , 32 , 33 , 34 , 35 ).…”